Skip to content
INDIASAY
Floor
PHARMA · US share of Indian pharma exports 34.61% FY25 [1]SPICES · FY25 exports US$ 4.72 bn — record volume and value [3]TEXTILES · US takes ~28% of Indian textile shipments [4]CHEMICALS · India specialty chemicals US$ 62.78 bn, 2024 [5]PHARMA · 670 USFDA-approved sites in India [1]SPICES · Chilli ~32% of India's spice export value [3]TEXTILES · Indo Count ~70% / Welspun ~60% US revenue exposure [4]CHEMICALS · Vinati Organics reports ~65% global share in IBB and ATBS [6]SPICES · Spice oils and oleoresins US$ 535.92 mn FY25 [3]PHARMA · Formulations and biologicals 75.74% of export value [2]
The regulated end of Indian supply. Finished dosage, active ingredients and contract manufacture, sold into markets that audit a site before they buy a kilogram from it.The regulated end of Indian supply. Finished dosage, active ingredients and contract manufacture, sold into markets that audit a site before they buy a kilogram from it.Adrien Olichon / Pexels

Industry 01 — ecosystem

Pharmaceuticals, APIs & CDMO

The regulated end of Indian supply. Finished dosage, active ingredients and contract manufacture, sold into markets that audit a site before they buy a kilogram from it.

Hyderabad · Mumbai · Ahmedabad · Visakhapatnam

PharmaceuticalsAPIsCDMOMedical Devices

What this industry lists

Indiasay licenses in audit evidence and records it — it does not certify
  • Active pharmaceutical ingredients (APIs), sold in bulk against a specification
  • Excipients
  • Pharmaceutical intermediates
  • CDMO capability — contract development and manufacturing
  • CMO capability — contract manufacturing

Does not list: Finished dosage forms bound for the United States.

A finished drug product sold into the US requires an ANDA or NDA holder of record, state-level wholesale distributor licensing, and unit-level DSCSA serialization. Indiasay holds none of these and does not broker around the requirement — a record that would need them does not list here. What this industry qualifies is the substance and the site, not a finished brand.

Market position

Attributed to the publication named, not asserted by Indiasay

US share of Indian pharma exports 34.61% FY25

[1]

670 USFDA-approved sites in India

[1]

Formulations and biologicals 75.74% of export value

[2]

[1] India Brand Equity Foundation — pharmaceutical and spice export briefs (ibef.org)

[2] Pharmexcil monthly export statement, as reported for May 2025

Certifications held across this industry

A manufacturer holding a certification is a fact about the site that holds it, with an issuing body and an expiry. Evidence is requested against your own written standard and recorded with the laboratory or audit firm that signed it.

USFDAEU GMPWHO GMPCEP / EDQMPMDATGAANVISAISO 9001DMF on file

Which manufacturers hold which of these is not yet recorded for this industry.

Documentation by destination

Pharma Ingredients & CDMOHS HS Chapter 29 (organic chemicals) for most bulk actives, intermediates and synthetic excipients; HS Chapter 28 for some inorganic actives. HS 3003/3004 (formulated, dosed medicaments) does not apply to anything in this category — see the exclusion below. · UAE and US requirements

Manufacturers represented

Positioning as published by the manufacturer. Verification state is stated, never implied.

Products on record — Pharmaceuticals, APIs & CDMO

Price is quoted against specification. Nothing is estimated.
Official product photograph required — MSN Group, API manufacturing — DMF portfolio (not itemised per molecule)Official product photograph required — MSN Group, API manufacturing — DMF portfolio (not itemised per molecule)Adrien Olichon / Pexels
MSN GroupAPI manufacturing — DMF portfolio (not itemised per molecule)Pharmaceuticals, APIs & CDMO
Specification
MSN Group's own regulatory page states an aggregate portfolio of 529 US DMFs, 181 EU DMFs and 160 CEPs across its API business as of the date accessed below. This is a company-level aggregate claim, not a per-molecule filing — no single molecule name or DMF number is asserted by this record.
Packing
Not published — quoted
MOQ
Not published — quoted
Open recordRequest quoteSubmit specification
Compiled from the manufacturer's own material ↗
Official product photograph required — Biophore India Pharmaceuticals, API manufacturing — niche and complex actives (not itemised per molecule)Official product photograph required — Biophore India Pharmaceuticals, API manufacturing — niche and complex actives (not itemised per molecule)Adrien Olichon / Pexels
Biophore India PharmaceuticalsAPI manufacturing — niche and complex actives (not itemised per molecule)Pharmaceuticals, APIs & CDMO
Specification
Biophore's own product listing (biophore.com/products.php) spans roughly 30 therapeutic segments and marks most entries "DMF Filed", with some marked "CEP" — but the page does not attach a DMF or CEP number to any single molecule, so no per-molecule filing is asserted here.
Packing
Not published — quoted
MOQ
Not published — quoted
Open recordRequest quoteSubmit specification
Compiled from the manufacturer's own material ↗
Official product photograph required — Signet Excipients, Pharmaceutical excipients — distribution portfolio (400+ excipients, 22 principals)Official product photograph required — Signet Excipients, Pharmaceutical excipients — distribution portfolio (400+ excipients, 22 principals)Adrien Olichon / Pexels
Signet ExcipientsPharmaceutical excipients — distribution portfolio (400+ excipients, 22 principals)Pharmaceuticals, APIs & CDMO
Specification
Distributes pharmaceutical excipients from 22 global principal manufacturers rather than manufacturing a single named molecule itself — no one molecule is asserted as this record's subject.
Packing
Not published — quoted
MOQ
Not published — quoted
Open recordRequest quoteSubmit specification

Related industries

Sharing capability with pharmaceuticals, apis & cdmo
13Medical DevicesAhmedabad · Chennai · Hyderabad